FINANCE/FUNDING ARTICLES

• Why It’s Never Too Early To Develop Your Exit Strategy

  It’s important to consider an exit strategy early in your process instead of waiting until there are challenges with liquidity, profitability, efficiency, lack of succession planning, and different partner expectations that would call for you to exit.

• Gearing Up For A Biotech M&A Boom

  Biotech M&A was slow in the first half of 2021, but that may be changing, with emerging trends indicating that a biotech M&A boom could be on the horizon. If your biotech is hoping to be acquired by a larger pharma company, it’s crucial that you start preparing now.

• VCs Breathe New Life Into Life Sciences Industrials

  The “industrials” or supplier sector of the biopharma industry, in a significant change from the past, is now receiving an extra financial boost from VC funding. Why should their biopharma customers care?

• IPO, M&A, And SPAC — 3 Life Science Execs Recount Going Public

  Taking a company public may not be every entrepreneur’s dream, but it is for many life sciences companies. As 2020 forever changed how IPOs are done, it seems like there is a great opportunity to capture some wisdom from those who have been there, done that.

• How To Identify Capital To Fund Life Sciences Growth

  For life sciences companies, funding needs evolve at every stage of growth — creating both challenges and opportunities. Regardless of the stage, it is fundamental to align your funding strategy with your company’s vision.

• Emerging Trends For Life Sciences IPOs During The Pandemic

  It is possible to take your company public without ever having to leave your home, but there are some key issues to consider when doing so.

• Dealmakers In Life Sciences: More Active, More Creative

  “Our belief is that the underlying strength of the life sciences sector will continue to promote dealmaking activity going forward, continuing its outperformance of other sectors.”

• The Evolving Payer Focus On Prevalence In Rare Diseases

  A recent analysis of trends in payer decisions related to reimbursement indicates that payers are looking at a range of issues, including disease prevalence, with new levels of scrutiny and are working to rein in pricing of many rare disease treatments.

• How To Overcome The Challenge Of Valuing A Biotech

  Because of the unknowns around revenue streams, biotech valuation may appear to be more guesswork than science. However, common valuation methods can help account for some of the product-line uncertainty.

• From Medtech CEO To Impact Investor — Not Your Typical Retirement Plan

  Tim Ring, former chairman and CEO of C.R. Bard, shares how he and his spouse retired to build TEAMFund, a $30 million impact investment fund focused on having a positive impact on health in some of the most resource constrained areas of the world.